Nexium

Cipla Q2 profit seen down 13%, lower Nexium sales may hit margin

Pharmaceutical firm Cipla's second quarter profit is seen falling 13.4 percent year-on-year to Rs 373.34 crore on dismal operational performance. However, revenue may increase 9 percent to Rs 3,763.2 crore compared with year-ago period, according to average of estimates of analysts polled by CNBC-TV18.

Cipla Q4 profit seen up 39%, likely to meet FY16 growth guidance

Analysts polled by CNBC-TV18 say that Cipla is ikely to meet FY16 guidance of 15 percent growth and 150 basis points (bps margin expansion. The company is likely to guide for 20 percent sales growth for FY17 on account of support from Invagen.

Dr Reddy's Labs gains 2%, relaunches anti-inflammatory drug

"Dr Reddy's today announced relaunch of its Esomeprazole magnesium delayed-release capsules (20 mg and 40 mg) in the US market," says the pharma major, adding the relaunch is due to a change in capsule colour.

Despite 3% rise, best to sell Dr Reddy's on Nexium woes?

Brokerages are still cautious on the stock as troubles do not seem to end for the Indian pharma company.

US imposes temporary sales ban on Dr Reddy's generic drug

The order was passed by the US district court of Delaware after AstraZeneca, the maker of Nexium, moved a motion objecting to the use of the colour purple in the Dr Reddy's copycat product, the Indian firm said in a statement.

Cipla Q2 profit seen up 74% on export formulation biz boost

Nexium (used to treat certain stomach and esophagus problem) & Pulmicort (used to prevent asthma attacks) supply may boost company's export formulation business during the quarter. Hence, export formulation business may grow around 35-40 percent year-on-year.

Sun Pharma withdraws lawsuit filed against USFDA by Ranbaxy

Valcyte (valganciclovir hydrochloride) is an antiviral drug. It is used in cytomegalovirus infections of eye. Nexium (esomeprazole) is used to treat certain stomach and esophagus problems.

Dr Reddy's Labs up 6%, launches gastric ulcer drug in US

"Dr Reddy‘s has launched Esomeprazole magnesium delayed-release capsules USP, 20 mg and 40 mg in the US market on September 25 following approval from US Food and Drug Administration," the drug major said in its filing.

Lupin up 4%; Credit Suisse upgrades, bets on diabetes drugs

Lupin has taken 200 percent price increase in Fortamet, according to Price Rx. The brokerage says it has been highlighting this opportunity for Lupin after a 8 times price increase in competing product Glumetza.

Cipla revises growth forecast to about 20% after strong Q1

Drug major Cipla reported a strong set of earnings for first quarter of FY16. CNBC-TV18's Archana Shukla caught up with the company's MD and CEO Subhanu Saxena and asked him about the drivers for this sales momentum.

Cipla rises 2%, Credit Suisse upgrades on firm Nexium sales

According to the brokerage, Nexium profits leading to strong earnings growth in H1FY16 and approval of generic Advair MDI in UK are strong near-term triggers of Cipla.

Lupin plunges 5%, Nomura downgrades to neutral, cuts target

Shares of Lupin fell 4.7 percent intraday Friday (in addition to 2.5 percent decline in previous session) after the brokerage Nomura downgraded the stock to neutral, citing slower US sales growth. Target price reduced to Rs 1,661 from Rs 1,738.

Expect FY16 US generic launch for Nexium: Lupin

In an interview with CNBC-TV18, CFO S Ramesh spoke to Latha Venkatesh and Sonia Shenoy about a recent acquisition and other developments such as a recent FDA audit at its Indore facility as well as its plans to launch a generic version of the world‘s second-largest-selling drug Nexium in the US.

Here's what JM Fin recommends buying in pharma space now

Among large caps, Anmol Ganjoo likes Dr. Reddy‘s Labs, Lupin and Cipla. He picks Ipca and Torrent Pharma from the mid cap space.

Teva to gain post Ranbaxy's exclusivity loss for Nexium

Ranbaxy has lost out on its last big drug opportunity in the US market. The US drug regulator has denied the company 180-day exclusivity for the generic version of heart burn drug Nexium. However Archana Shukla reports that Ranbaxy's loss means good times for global rival Teva and Cipla.

'Ranbaxy's Nexium generic loss may up Cipla's EPS 3-5%'

The US FDA‘s decision to revoke the 180-day exclusivity cover extended to Indian firm Ranbaxy to sell a generic version of the world‘s second-largest selling drug esomeprazole is likely to help rival Cipla, according to Vivek Kumar, research analyst, SBICap Securities.